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ABSTRACT
Deleted in colorectal carcinoma (DCC), a netrin-1 dependence receptor, is
correlated with cell progression, migration, and adhesion. Evidence indicated that DCC
was frequently down-regulated in many cancers. However, the association of DCC with
breast cancer remains uncertain. We conducted a case-control study to investigate the
impact of three DCC gene variants (rs2229080, rs7504990, and rs4078288) on breast
cancer susceptibility in Chinese women. This study included 560 breast cancer patients
and 583 age-matched healthy controls from Northwest China. The three gene variants
were genotyped via Sequenom MassARRAY. Odds ratios (ORs) and 95% confidence
intervals (CIs) were utilized to evaluate the associations. We found that individuals
with the rs2229080 C/G, C/C, and C/G-CC genotypes had a higher breast cancer risk,
and the minor allele C was associated with increased breast cancer risk in an allele
model. We observed a significantly decreased breast cancer risk with the rs7504990
C/T, T/T, and C/T-T/T genotypes, and the minor allele T was protective against breast
cancer in an allele model. In addition, rs2229080 was associated with the axillary
lymph node (LN) metastasis status. An age-stratified analysis revealed an association
between rs2229080 and reduced breast cancer risk among older patients (≥ 49 years).
Furthermore, the haplotype analysis showed that the Crs2229080Crs7504990Ars4078288 haplotype
was associated with a decreased breast cancer risk. However, the results indicated a
lack of association between rs4078288 and breast cancer risk. These findings affirmed
that rs2229080 and rs7504990 polymorphisms in DCC might be related with breast
cancer susceptibility in Chinese women.

INTRODUCTION

In the nervous system, axon development is guided
by diffusible chemoattractants produced by axonal target
cells [4]. Netrins, a family of extracellular proteins, are
considered critical axon guidance cues for the positioning
of axonal growth during neural circuit formation and
various biological processes, including tumorigenesis,
adhesion, and angiogenesis [5]. Netrin-1 and netrin-4 are
the most frequently studied members of the netrin family
[6]. Netrin-1 expression is elevated in human renal clear
cell carcinomas relative to normal tissues [7]. Netrin-1
overexpression is considered a poor prognostic factor
in ovarian malignancies [8]. A complete loss of netrin-1
causes embryonic death and severe axon guidance defects

Breast cancer (BC) is the most common type
of tumors in women worldwide, with 1.8 million
incident cases and 464,000 death cases in 2013 [1].
Approximately 5% to 10% of BCs are metastatic at
diagnosis, and of these, approximately one-fifth of the
affected patients will survive for 5 years [2]. A previous
study estimated that the expression of axon guidance
molecules (AGMs) was dysregulated during BC
tumorigenesis and tumor progression, suggesting that
AGMs might act as tumor suppressors and oncogene
activators [3].
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in mice [9]. Netrin-1 receptors such as DCC and SAX-3
(Robo) can function individually or in combination with
other guidance receptors to control axon growth [10].
Evidence shows that DCC is widely expressed by neurons
and is enriched at synapses to promote synaptogenesis
between mammalian cortical neurons [11]. In addition,
DCC can induce apoptosis in the absence of its ligand
netrin-1 [12].
Recently researchers are mostly focused on the
association between rs2229080, rs7504990 and rs4078288
polymorphisms in DCC and many cancers. Rs2229080 is
located on human chromosome 18, with a C/G singlenucleotide variation, which may alter the DCC expression.
Rs7504990 and rs4078288 are located in the intron region
and may not directly affect protein function. Rai et al. [13]
did not confirm rs4078288 and rs7504990 polymorphisms
as the risk factors for gallbladder cancer, different with
the results of GWAS. However, to our knowledge, there
were no studies involved the association between the
three DCC polymorphisms and BC susceptibility. In this
case-control study, we aimed to examine the association
of these three DCC gene polymorphisms (rs2229080,
rs7504990, and rs4078288) with BC risk in a Northwest
Chinese population.

rs2229080 polymorphism, we found that C/G, C/C, and
C/G-CC genotype carriers had a significantly increased
risk of developing BC (OR > 1, P < 0.05); the same trend
was observed for patients with the C allele (P = 0.007).
For rs7504990, patients with BC were less likely than
controls to carry the C/T, T/T, and C/T-T/T genotypes
(32.3% vs. 38.9%, 5.9% vs. 8.2%, and 38.2% vs. 47.2%,
respectively), and the minor allele T conferred a reduced
risk to BC in an allele model (OR = 0.74, 95% CI = 0.61–
0.89, P = 0.002). However, the patients and controls did
not differ significantly with respect to the frequency of
any rs4704853 genotypes (P > 0.05). We also obtained the
statistical power of 0.86 and 0.83 for the two significant
polymorphisms identified, rs2229080 and rs7504990,
respectively. This showed that our sample size of 1143
was adequate and the study was sufficiently able to detect
the true association of these two polymorphisms with BC.

Association between DCC gene variants and
clinical parameters of patients with BC
To investigate whether DCC variants were associated
with the clinical features of patients with BC, we further
analyzed the distributions of DCC variants with respect to
a series of clinicopathological parameters including tumor
size; axillary lymph node (LN) metastasis; and estrogen
receptor (ER), progesterone receptor (PR), human epidermal
growth factor receptor 2 (HER-2), and Ki67 index statuses.
As shown in Table 3, rs2229080 was associated with
LN metastais in patients with BC (P = 0.01). However,
no significant correlations were detected between the
rs7504990 or rs4704853 polymorphisms and clinical
features of patients with BC (data not shown).

RESULTS
Characteristics of the patients and controls
The characteristics of the 560 BC cases and
583 controls are presented in Table 1. The mean ages of
patients with BC and healthy controls were 49.09 ± 11.02
and 48.80 ± 8.28 years, respectively. No significant
differences were noted between BC cases and controls in
terms of the age distribution (P = 0.612) and menopausal
status (P = 0.716). However, the body mass index of
BC patients significantly differed from health controls
(P = 0.038). Therefore, statistical analysis based on casecontrol comparisons was adjusted for BMI.

Stratified analysis of DCC gene variants and BC
risk
The results of a stratified analysis are shown in
Table 4. When the participants were stratified according
to age, differences in DCC rs7504990 polymorphism
distribution were not statistically significant. However,
for DCC rs2229080, the GA + AA genotype was
significantly expressed lower frequency among
older participants (age ≥ 49 years) (OR = 0.65, 95%
CI = 0.46–0.91, P = 0.01).

Association between DCC gene variants and BC
risk
All three SNPs of DCC gene were successfully
genotyped in 560 patients and 583 controls. The genotypes
and allele frequencies of the DCC rs2229080, rs7504990,
and rs4078288 variants are shown in Table 2 and Figure 1.
The genotype distributions of the three SNPs in healthy
controls exhibited Hardy–Weinberg Equilibrium (HWE)
(P = 0.07, 0.50, and 0.99 for rs2229080, rs7504990, and
rs4078288, respectively), indicating that community
genetic inheritance was balanced in the control samples
and that these samples could represent the general
population.
Among all selected DCC polymorphisms, two
were found to be associated with the risk of BC. For the
www.impactjournals.com/oncotarget

Associations between DCC haplotypes
and BC risk
We then evaluated the relationship between
haplotypes and BC risk. Compared with the common
haplotype Grs2229080Crs7504990Ars4078288, the haplotype
Crs2229080Crs7504990Ars4078288 was associated with a decreased
BC risk (OR = 0.74, 95% CI = 0.61–0.90, P = 0.003,
Table 5). We also observed a significant association
between other haplotypes and BC risk (P < 0.001).
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Table 1: Distributions of select variables in breast cancer cases and cancer-free controls
Cases

Control

P value*

Number
Age (mean ± SD)

560
49.09 ± 11.02

583
48.80 ± 8.28

0.612

Menopausal status
Premenopausal

264

281

296

302

0.716

22.95 ± 3.21

0.038

< 2 cm
≥ 2 cm
Negative
Positive
Negative

22.52 ± 2.84
188
372
236
324
247

Positive

313

Negative

255

Positive

305

Negative

389

Positive

171

< 14%

195

≥ 14%

365

Characteristics

Postmenopausal
Body mass index (kg/m )
(mean ± SD)
Tumor size
2

LN metastasis
ER
PR
Her-2
Ki67

*T-test or two-sided χ2-test.
LN: Axillary lymph node; ER: Estrogen receptor; PR: Progesterone receptor; HER-2: human epidermal growth factor
receptor 2.

DISCUSSION

no significant role for DCC alterations has been found in
the pathogenesis of meningiomas [23].
In previous studies, DCC gene variants were found
to be correlated with some types of cancer. Rai et al.
[13] found that the DCC haplotype G (rs2229080)-A
(rs4078288)-C (rs7504990)-A (rs714) conferred a
high risk of gallbladder cancer. The rs714 (A > G)
polymorphism contributes to the risk of esophageal and
gastric cancers in a Kashmiri population [24]. To date, the
possible effects of DCC variants had not been studied in
BC. In our study, we have provided the initial observation
that the DCC genotype variants rs2229080 and rs7504990,
but not rs4078288, contributed differentially to BC
susceptibility. The haplotype Crs2229080Crs7504990Ars4078288 had
a significant relationship with decreased BC risk.
A previous study found increased DCC expression but
a lower rate of axillary lymph node metastasis in mucinous
carcinoma than in non-mucinous carcinoma in the human
female breast [25]. DCC-negative, HER-2 overexpressing
tumors were found to have a marginal influence on the
survival duration of patients with BC, indicating that
reduced DCC expression and HER-2 overexpression might
influence the prognosis of BC [26]. However, that finding
differs from our results. According to our study, the DCC

DCC is a single-pass transmembrane protein
that belongs to the immunoglobulin superfamily, and
it is a candidate tumor suppressor gene located on
chromosome 18q21 [14]. DCC extends more than 1.2 Mb
with 29 exons [15], and is the largest tumor suppressor
gene identified to date. It is expressed in most normal
tissues, including the colonic mucosa, and its expression
was greatly reduced or absent in most tested colorectal
carcinomas [16]. DCC directs cell invasion through the
basement membrane, an essential step in the pathological
progression of human cancer [17]. Currently, DCC
is known to be involved in the following biological
processes: guidance of developing axons,4 induction of
apoptosis [18], control of colorectal tumorigenesis [19],
and angiogenesis [20]. DCC alterations are apparent in
early-stage gastric cancers, emphasizing the importance of
this growth regulatory pathway in gastric carcinogenesis
[21]. Significant differences were observed between
cases without metastasis or local recurrences versus
those with metastasis or local recurrences, suggesting
that a decrease in DCC expression might influence the
prognosis of patients with breast cancer [22]. However,
www.impactjournals.com/oncotarget
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Table 2: Genotype and allele frequencies of the DCC polymorphisms among the cases and controls
and the associations with breast cancer risk
Model

Genotype

P-value*

Case (560)

Control (583)

OR (95% CI)†

G/G

158 (28.2%)

212 (36.3%)

1.00 (reference)

C/G

313 (55.9%)

296 (50.8%)

1.42
(1.09–1.84)

0.008

CC

89 (15.9%)

75 (12.9%)

1.59
(1.10–2.31)

0.013

GG

158 (28.2%)

212 (36.3%)

1.00 (reference)

C/G-C/C

402 (71.8%)

371 (63.7%)

1.45
(1.13–1.87)

G/G-C/G

471 (84.1%)

508 (87.1%)

1.00 (reference)

C/C

89 (15.9%)

75 (12.9%)

1.28
(0.92–1.78)

G

629 (56.2%)

720 (61.7%)

1.00 (reference)

C

491 (43.8%)

446 (38.3%)

1.26
(1.07–1.49)

C/C

346 (61.8%)

308 (52.8%)

1.00 (reference)

C/T

181 (32.3%)

227 (38.9%)

0.71 (0.55–0.91)

0.007

T/T

33 (5.9%)

48 (8.2%)

0.61 (0.38–0.98)

0.039

C/C

346 (%)

308 (52.8%)

1.00 (reference)

C/T-T/T

214 (38.2%)

275 (47.2%)

0.69 (0.55–0.88)

C/C-C/T

527 (94.1%)

535 (91.8%)

1.00 (reference)

T/T

33 (5.9%)

48 (8.2%)

0.70 (0.44–1.11)

C

873 (77.9%)

843 (72.3%)

1.00 (reference)

T

247 (22.1%)

323 (27.7%)

0.74 (0.61–0.89)

A/A

307 (54.8%)

304 (52.1%)

1.00 (reference)

G/A

212 (37.9%)

234 (40.1%)

0.90 (0.70–1.15)

0.384

G/G

41 (7.3%)

45 (7.7%)

0.90 (0.57–1.42)

0.655

A/A

307 (54.8%)

304 (52.1%)

1.00 (reference)

G/A-G/G

253 (45.2%)

279 (47.9%)

0.90 (0.71–1.13)

A/A-G/A

519 (92.7%)

538 (92.3%)

1.00 (reference)

G/G

41 (7.3%)

45 (7.7%)

0.94 (0.61–1.47)

A

826 (73.8%)

842 (72.2%)

1.00 (reference)

G

294 (26.2%)

324 (27.8%)

0.93 (0.77–1.11)

rs2229080   HWE = 0.07
Codominant

Dominant

Recessive

Allele

0.003

0.144

0.007

rs7504990   HWE = 0.50
Codominant

Dominant
Recessive
Allele

0.002
0.123
0.002

rs4078288   HWE = 0.99
Codominant

Dominant
Recessive
Allele

0.364
0.799
0.408

Two-sided χ2 test for the distributions of genotype and allele frequencies.
Adjusted for age and body mass index.

*
†
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rs2229080 polymorphism was associated with the lymph
node metastasis status. Furthermore, rs2229080 conferred
a decreased BC risk in older individuals (≥ 49 years). Our
results demonstrate that the rs2229080 polymorphism
might play a critical role in BC susceptibility. Moreover,
DCC rs2229080 polymorphism was reported to occur more
frequently in stages C and D in colorectal cancer, and may
serve as a prognostic factor for colorectal cancer patients
[27]. Rs2229080 polymorphism is located in the coding
region, which may decrease DCC gene expression. The
expression of DCC is mostly lost or reduced in later clinical
stage, higher pathological grade, and poor prognosis in
ovarian cancer [28].
Our study had some limitations. First, the sample
size was inadequate for a stratified analysis and for an
analysis of these associations in patients with mix-type

BC. As this is the first report of genetic BC susceptibility
related to DCC polymorphism, similar studies with larger
sample sizes will be needed for further verification.
Second, we did not investigate whether predisposing
factors, including high-dose radiation exposure, alcohol
consumption, and postmenopausal obesity, were associated
with the risk of BC because of a lack of such data from
both BC patients and healthy controls. The effect of these
factors on BC risk should be assessed in a future study.
In conclusion, our case-control study indicates
that the rs2229080 and rs7504990 polymorphisms in
DCC might affect BC susceptibility and progression in
Chinese women. Further functional studies and large
population-based prospective studies will be needed to
provide accurate evidence about the influence of DCC
variants on BC.

Figure 1: (A) Genotype frequencies of the DCC polymorphisms among the cases and controls. (B) Allele frequencies of the DCC
polymorphisms among the cases and controls. (A) the major allele; (B) the minor allele.
www.impactjournals.com/oncotarget
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Table 3: The associations between the DCC polymorphisms and clinical characteristics of breast
cancer patients
Variables

rs2229080
G/G (%)

Tumor size
< 2 cm
54 (28.7%)
104
(28.0%)
LN metastasis
Negative
81 (37.3%)
≥ 2 cm

C/G+C/C(%)

P*

P*

OR (95%CI)

CC (%)

C/T+T/T (%)

1.00 (reference)

127 (67.6%)

61 (32.4%)

1.00 (reference)

0.85 1.04 (0.70–1.53) 219 (58.9%)

153 (41.1%)

0.05 1.46 (1.01–2.10)

143 (60.1%)

93 (39.4%)

1.00 (reference)

0.01 1.68 (1.16–2.43) 203 (62.7%)

121 (37.3%)

0.62 0.92 (0.65–1.29)

134 (71.3%)
268
(72.0%)

rs7504990

155 (62.7%)

1.00 (reference)

OR (95%CI)

77
(23.8%)

247
(76.2%)

Negative

61
(24.7%)

186
(75.3%)

1.00 (reference)

148
(60.0%)

99
(40.0%)

1.00 (reference)

Positive

97 (31.0%)

216
(69.0%)

0.10 0.73 (0.50–1.06)

198
(63.3%)

115
(36.7%)

0.42 0.87 (0.62–1.22)

69
(27.1%)

186
(72.9%)

1.00 (reference)

155 (60.8%)

100 (39.2%)

1.00 (reference)

89 (29.2%)

216 (70.8%)

0.58 0.90 (0.62–1.30) 191 (62.6%)

114 (37.4%)

0.66 0.93 (0.66–1.30)

115
(29.6%)

274
(70.4%)

246 (63.2%)

143 (36.8%)

1.00 (reference)

43 (25.1%)

128 (74.9%)

0.29 1.25 (0.83–1.88) 100 (58.5%)

71 (41.5%)

0.29 1.22 (0.85–1.76)

< 14%

57
(29.2%)

138
(70.8%)

≥ 14%

101
(27.7%)

264
(72.3%)

Positive
ER

PR
Negative
Positive
HER-2
Negative
Positive
Ki67

1.00 (reference)

0.70

1.00 (reference)

119
(61.0%)

76
(39.0%)

1.08
(0.74–1.59)

227
(62.2%)

138
(37.8%)

1.00 (reference)
0.79

0.95
(0.67–1.36)

Two-sided χ2 test for the distributions of genotype frequencies.
LN: Axillary lymph node; ER: Estrogen receptor; PR: Progesterone receptor; HER-2: human epidermal growth factor
receptor 2.
*

MATERIALS AND METHODS

age. All patients met the present pathological criteria of
sporadic BC and were diagnosed between January 2013
and October 2014 at the Second Affiliated Hospital of
Xi’an Jiaotong University, China. Patients who had
other types of cancer were excluded from the study. The
controls were randomly selected from among healthy
volunteers who underwent annual physical examinations
in other hospital departments and who had no prior history
of cancer. Controls were frequency matched to patients
according to age (±5 years). The methods were performed
in accordance with the approved guidelines. All research
participants provided written informed consent and were
interviewed to obtain detailed information regarding age,
sex, ethnicity, religion, place of residence, education, and
other potential confounding factors of interest. After the

Ethics statement
The study was approved by the Institutional
Review Board of Xi’an Jiaotong University (Xi’an,
China). Written informed consent was obtained from
all participants involved in the study at the time of
recruitment.

Study population
We conducted a hospital-based case-control study
of 560 BC patients and 583 cancer-free controls. All
participants were recruited without the restrictions of
www.impactjournals.com/oncotarget
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Table 4: Stratified analyses on association between DCC polymorphisms and breast cancer risk
rs2229080
Genotypes

Age < 49
G/G
C/G + CC
Age ≥ 49
G/G
C/G + CC

Case
(N = 560)
N (%)

rs4704853

Control
(N = 583)
N (%)

P*

OR
(95%CI)†

Genotypes

73
(27.7%)
191
(72.3%)

94
(34.2%)
181
(65.8%)

1.00
(reference)
0.10
0.74
(0.51–1.06)

85
(28.7%)
211
(71.3%)

118
(38.3%)
190
(61.7%)

1.00
(reference)
0.01
0.65
(0.46–0.91)

Age < 49
C/C
C/T + T/T
Age ≥ 49
C/C
C/T + T/T

Case
(N = 560)
N (%)

Control
(N = 583)
N (%)

149
(56.7%)
114
(43.3%)

107
(48.6%)
113
(51.4%)

197
(66.3%)
100
(33.7%)

201
(66.3%)
102
(33.7%)

P*

0.08

1.00

OR (95% CI)†

1.00
(reference)
1.38
(0.96–1.98)
1.00
(reference)
1.00
(0.71–1.40)

*Two-sided χ2 test for the distributions of genotype frequencies.
†
Adjusted for age and age at menarche.

Table 5: Association between DCC haplotypes and breast cancer risk
Haplotypes
rs2229080

rs7504990

rs4078288

Controls
(N = 1166)
n, %

G

C

A

416 (35.68%)

Cases
(N = 1120)
n, %
348 (31.07%)

G

T

G

296 (25.39%)

226 (20.18%)

C

C

A

420 (36.02%)

473 (42.23%)

C

T

G

21 (1.80%)

16 (1.43%)

13 (1.11%)

57 (5.09%)

Others

OR
(95% CI)

P

1.00 (reference)
1.10
(0.88–1.37)
0.74
(0.61–0.90)
1.10
(0.56–2.14)
0.19
(0.10–0.35)

0.424
0.003
0.783
< 0.001

Table 6: Primers used for this study
SNP_ID

1st-PCRP
ACGTTGGATGGCTGAGCA
TCGGTAAATTCC

2nd-PCRP
ACGTTGGATGTCTTGCCCTC
TGGAGCATTG

rs7504990

ACGTTGGATGCCAAATCTG
CTATTACTCAC

ACGTTGGATGCCAAGTTATG
TTGGACAGAG

rs4078288

ACGTTGGATGTAGGGAACA
AGAGAGAGTGC

ACGTTGGATGCTTCTATTGGT
GGTAATGAGCTATTGGAACTA
CTAGAGGTG

rs2229080

interview, approximately 2 mL of venous blood sample
was collected from each healthy control and breast
cancer patient before they received the chemotherapy or
radiotherapy .

TGGAGCATTGCAGATCAGC
tCCACACACTTATTGGCAGAT

a standard phenol-chloroform extraction method. DNA
concentrations were measured via spectrometry (DU530
UV/VIS spectrophotometer; Beckman Instruments,
Fullerton, CA, USA). For our study, we selected candidate
SNPs in TIM according to HapMap data from a Chinese
population. To achieve a power of at least 50%, only
SNPs with a minor allele frequency (MAF) > 0.01 was
included. Sequenom MassARRAY Assay Design 3.0
Software (Agena Bioscience, San Diego, CA, USA)
was used to design a Multiplexed SNP MassEXTEND

Genotyping assay
Whole blood samples were placed into EDTA-coated
tubes and preserved at −80°C until further use. Genomic
DNA was isolated from the whole blood samples using
www.impactjournals.com/oncotarget
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assay. Finally, three SNPs (rs2229080, rs7504990, and
rs4078288) were selected according to Chinese population
data from HapMap. DCC SNP genotyping was performed
using a Sequenom MassARRAY RS1000, according to the
manufacturer’s instructions. The corresponding primers
used for each SNP in this study are listed in Table 6.
Sequenom Typer 3.0 Software (Sequenom Inc., San
Diego, CA, USA) was used for data analysis.
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